(Q36611047)

15 August 2017

1 reference

title

A review of work-participation, cost-of-illness and cost-effectiveness studies in ankylosing spondylitis (English)

1 reference

cost-effectiveness analysis

15 August 2017

main subject

1 reference

1

Annelies Boonen

1 reference

15 August 2017

publication date

1 October 2006

1 reference

Nature Clinical Practice Rheumatology

15 August 2017

published in

1 reference

15 August 2017

volume

2

1 reference

15 August 2017

issue

10

1 reference

15 August 2017

page(s)

546-553

1 reference

Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors.

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0297

Application of the International Classification of Functioning, Disability and Health (ICF) in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0297

Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0297

Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0297

Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0297

76 patients with ankylosing spondylitis seen after 30 years of disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0297

Long-term disability and prolonged sick leaves as outcome measurements in ankylosing spondylitis. Possible predictive factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0297

Employment, work disability, and work days lost in patients with ankylosing spondylitis: a cross sectional study of Dutch patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0297

Withdrawal from labour force due to work disability in patients with ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0297

Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0297

A review of 100 patients with ankylosing spondylitis with particular reference to socio-economic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0297

The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0297

Direct costs of ankylosing spondylitis and its determinants: an analysis among three European countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0297

Large differences in cost of illness and wellbeing between patients with fibromyalgia, chronic low back pain, or ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0297

Functional disability predicts total costs in patients with ankylosing spondylitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0297

Review of the costs of illness of ankylosing spondylitis and methodologic notes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0297

Markov model into the cost-utility over five years of etanercept and infliximab compared with usual care in patients with active ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0297

EuroQol--a new facility for the measurement of health-related quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0297

The risk of developing ankylosing spondylitis in HLA-B27 positive individuals. A comparison of relatives of spondylitis patients with the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0297

7 January 2021

Overestimation of the prevalence of ankylosing spondylitis in the Berlin study: comment on the article by Braun et al

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0297

7 January 2021

Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0297

7 January 2021

Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0297

7 January 2021

Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT)

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0297

7 January 2021

Work disability among people with ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0297

7 January 2021

Cost effectiveness of combined spa-exercise therapy in ankylosing spondylitis: A randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0297

7 January 2021

Identifiers

DOI

10.1038/NCPRHEUM0297

1 reference

15 August 2017

1 reference